{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Talla A"],"funding":["U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)"],"pagination":["505-517"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12920136"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["32(2)"],"pubmed_abstract":["Antiretroviral therapy (ART) suppresses HIV but does not eliminate the latent viral reservoir, which persists in programmed cell death protein 1 (PD-1)-expressing CD4<sup>+</sup> T cells. Anti-PD-1 therapies have reduced the HIV reservoir in people living with HIV (PLWH) and cancer; however, the individuals who benefit and the mechanisms driving reservoir reduction remain unclear. We performed a prespecified exploratory, longitudinal multiomic profiling of 30 PLWH (29 males and one female) with cancer in the phase 1 CITN-12 clinical trial, in which pembrolizumab was evaluated for safety and preliminary antitumor activity. The therapy was generally well tolerated, with most adverse events graded 1-2 and objective antitumor response observed in five participants (one complete response and fo"],"journal":["Nature medicine"],"pubmed_title":["Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy."],"pmcid":["PMC12920136"],"funding_grant_id":["P01AI178376","UM1AI164561"],"pubmed_authors":["Azevedo JLLC","Bal SK","Maldarelli F","Lewin SR","Cheever MA","Pelletier AN","Lurain K","D'Amico L","Ramaswami R","Sekaly RP","Fling SP","Sharma AA","Enriquez AB","Talla A","Sharon E","Martinez-Picado J","Latif MB","Chomont N","Sanchez GP","Kumari S","Ghneim K","Yarchoan R","Schuch V","Rhodes A","Hess BW","Uldrick TS","Deeks SG"],"additional_accession":[]},"is_claimable":false,"name":"Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy.","description":"Antiretroviral therapy (ART) suppresses HIV but does not eliminate the latent viral reservoir, which persists in programmed cell death protein 1 (PD-1)-expressing CD4<sup>+</sup> T cells. Anti-PD-1 therapies have reduced the HIV reservoir in people living with HIV (PLWH) and cancer; however, the individuals who benefit and the mechanisms driving reservoir reduction remain unclear. We performed a prespecified exploratory, longitudinal multiomic profiling of 30 PLWH (29 males and one female) with cancer in the phase 1 CITN-12 clinical trial, in which pembrolizumab was evaluated for safety and preliminary antitumor activity. The therapy was generally well tolerated, with most adverse events graded 1-2 and objective antitumor response observed in five participants (one complete response and fo","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T12:38:02.896Z","creation":"2026-07-09T10:55:01.389Z"},"accession":"S-EPMC12920136","cross_references":{"pubmed":["41680482"],"doi":["10.1038/s41591-025-04139-y"]}}